Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study()

There is currently an outbreak of respiratory disease caused by a novel coronavirus. The virus has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease it causes has been named coronavirus disease 2019 (COVID-19). More than 16% of patients developed acute respirato...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Qingxian, Yang, Minghui, Liu, Dongjing, Chen, Jun, Shu, Dan, Xia, Junxia, Liao, Xuejiao, Gu, Yuanbo, Cai, Qiue, Yang, Yang, Shen, Chenguang, Li, Xiaohe, Peng, Ling, Huang, Deliang, Zhang, Jing, Zhang, Shurong, Wang, Fuxiang, Liu, Jiaye, Chen, Li, Chen, Shuyan, Wang, Zhaoqin, Zhang, Zheng, Cao, Ruiyuan, Zhong, Wu, Liu, Yingxia, Liu, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company. 2020
Materias:
Research Coronavirus Disease 2019—Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185795/
https://www.ncbi.nlm.nih.gov/pubmed/32346491
http://dx.doi.org/10.1016/j.eng.2020.03.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185795/
https://www.ncbi.nlm.nih.gov/pubmed/32346491
http://dx.doi.org/10.1016/j.eng.2020.03.007

Ejemplares similares